TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20384598

Group type: EXPERIMENTAL
Intervention: Sertindole
Number of subjects: 9858

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 9858
Study: 18695086

Group type: EXPERIMENTAL
Intervention: HbA(1c) levels
Number of subjects: 2412
Study: 15923969

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study: 12629105

Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg cocaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 10576189

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 50 microg every 4 hours as needed
Number of subjects: 108

Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral misoprostol and Intravenous oxytocin
Number of subjects: 108
Study: 8740599

Group type: EXPERIMENTAL
Intervention: Experimental back muscle pain induced by bolus injection of 5% hypertonic saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Chronic low back pain (CLBP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (sex- and age-matched)
Number of subjects: 10
Study: 1662638

Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1, 250 mg on days 2-5)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Cephalexin (500 mg b.i.d. for ten days)
Number of subjects: 366
Study: 7046908

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg/m2 orally three times a week) with chemotherapy
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Reduced dosage of levamisole (2.5 mg/kg or 100 mg/m2 three times a week, every other week) with chemotherapy
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control regimen (chemotherapy without levamisole)
Number of subjects: 381
Study: 30799154

Group type: EXPERIMENTAL
Intervention: Self-management goals in nursing visits (pain management, fall prevention)
Number of subjects: 367
Study: 28657417

Group type: EXPERIMENTAL
Intervention: Aspirin (150 mg per day)
Number of subjects: 1776

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1776
Study: 25646169

Group type: EXPERIMENTAL
Intervention: Toothpaste containing fluoride, triclosan, cetylpyridinium chloride, and essential oils
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fluoridated toothpaste (control)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 40
Study: 23543398

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 3014

Group type: COMPARATOR
Intervention: No Clopidogrel
Number of subjects: 3014
Study: 21845387

Group type: EXPERIMENTAL
Intervention: Local injection of dexamethasone (8 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral administration of dexamethasone (8 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 67
Study: 20535250

Group type: EXPERIMENTAL
Intervention: 6 mm PTFE graft
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 8 mm PTFE graft
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients with underlying diseases (hypertension and diabetes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients without underlying diseases
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Complication rates in patients with underlying diseases
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Complication rates in patients without underlying diseases
Number of subjects: 102

Group type: COMPARATOR
Intervention: Comparison of graft sizes
Number of subjects: 102
Study: 16167288

Group type: EXPERIMENTAL
Intervention: Fixed-combination brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution dosed BID (n = 188)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Concomitant brimonidine tartrate 0.2% BID and timolol 0.5% BID (n = 183)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both treatments (fixed-combination and concomitant)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 371
Study: 14634377

Group type: EXPERIMENTAL
Intervention: Shock wave lithotripsy with ventricular arrhythmias
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no arrhythmias)
Number of subjects: 51
Study: 10656431

Group type: EXPERIMENTAL
Intervention: FEC (fluorouracil, epirubicin, cyclophosphamide)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 67
Study: 8679790

Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH intravenously 20 min before ECT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo intravenously 20 min before ECT
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH just prior to ECT
Number of subjects: 14

Group type: COMPARATOR
Intervention: ECT alone
Number of subjects: 14
Study: 2066545

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime and Placebo
Number of subjects: 0
Study: 6606576

Group type: EXPERIMENTAL
Intervention: Surgical treatment (aorto-coronary bypass surgery)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 76
Study: 31298720

Group type: EXPERIMENTAL
Intervention: EDOF only group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Mixed group
Number of subjects: 80
Study: 27056697

Group type: EXPERIMENTAL
Intervention: High-flexion protocol (70° of knee flexion)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Mild-flexion protocol (30° of knee flexion)
Number of subjects: 85
Study: 26280534

Group type: EXPERIMENTAL
Intervention: Iron supplementation (60 mg)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study: 25102458

Group type: EXPERIMENTAL
Intervention: Pre‐fabricated primary zirconia crowns
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pre‐veneered stainless steel crowns (SSCs)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Composite strip crowns
Number of subjects: 39
Study: 23139692

Group type: EXPERIMENTAL
Intervention: Melatonin (3 or 6 mg based on weight) combined with Ritalin (1mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo combined with Ritalin (1mg/kg)
Number of subjects: 50
Study: 19862405

Group type: EXPERIMENTAL
Intervention: Sof-Lex Pop-on disks (3M ESPE)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Astropol and Astrobrush system (Ivoclar Vivadent)
Number of subjects: 36
Study: 17523910

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day for 4 weeks (group C)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day for 4 weeks (group D)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Doxazosin (group D)
Number of subjects: 73
Study: 15930063

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 12912782

Group type: EXPERIMENTAL
Intervention: Personalized weight and fitness health report card (PI)
Number of subjects: 1396

Group type: EXPERIMENTAL
Intervention: General-information intervention (GI)
Number of subjects: 1396

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 1396
Study: 10583314

Group type: EXPERIMENTAL
Intervention: Washing of testosterone pellets
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control group (no washing)
Number of subjects: 251
Study: 8911190

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy (7.5 pulses-per-second mode)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional fluoroscopy
Number of subjects: 401

Group type: COMPARATOR
Intervention: Pulsed fluoroscopy control group
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional fluoroscopy control group
Number of subjects: 401
Study: 1905949

Group type: EXPERIMENTAL
Intervention: 50 micrograms EE
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 50 micrograms EE with 250 micrograms levonorgestrel (LNG)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 250 micrograms levonorgestrel (LNG) alone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 250 micrograms levonorgestrel (LNG) with 50 micrograms EE
Number of subjects: 6
Study: 6342353

Group type: EXPERIMENTAL
Intervention: Prazosin 20 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 31755292

Group type: EXPERIMENTAL
Intervention: collagen 4 ml
Number of subjects: 0

Group type: COMPARATOR
Intervention: trimecaine 1% 4 ml
Number of subjects: 0
Study: 29735869

Group type: EXPERIMENTAL
Intervention: Cyclic diclofenac potassium (DP) regimen (50 mg, twice daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 27043165

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 3026

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 3026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3026
Study: 25457123

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST) - six 1-hour sessions
Number of subjects: 37

Group type: COMPARATOR
Intervention: Social contact comparison (6 'friendly' visits)
Number of subjects: 37
Study: 23284689

Group type: EXPERIMENTAL
Intervention: SRT2104 (0.5 or 2.0 g)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20559637

Group type: EXPERIMENTAL
Intervention: Hepatectomy with Pringle maneuver (HPC group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hepatectomy without Pringle maneuver (NHPC group)
Number of subjects: 80
Study: 17562226

Group type: EXPERIMENTAL
Intervention: Whole-grain based dietary product (WG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nutrient-dense meal replacement product (MR)
Number of subjects: 31
Study: 15707388

Group type: EXPERIMENTAL
Intervention: CC carriers
Number of subjects: 715

Group type: COMPARATOR
Intervention: AA carriers
Number of subjects: 715
Study: 12072722

Group type: EXPERIMENTAL
Intervention: Desonide 0.25% ophthalmic solution
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fluorometholone
Number of subjects: 108
Study: 9491286

Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of intravenous iron dextran (Imferon)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Divided doses of 100 mg intravenous iron dextran administered on 6 successive dialyses
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weekly doses of intravenous iron dextran for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: All groups (I, II, III)
Number of subjects: 43
Study: 8559906

Group type: EXPERIMENTAL
Intervention: Initial evaluations (30 students)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reevaluations (30 students)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Homeroom teachers (60 teachers)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Elementary and secondary school placement
Number of subjects: 60
Study: 2226542

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy (alteplase) initiated early
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thrombolytic therapy (alteplase)
Number of subjects: 0
Study: 847785

Group type: EXPERIMENTAL
Intervention: Regulated bed rest for three weeks
Number of subjects: 187
Study: 31884683

Group type: EXPERIMENTAL
Intervention: MIX (menthol swilling with crushed ice ingestion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MENTH (menthol swilling with water ingestion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (control)
Number of subjects: 12
Study: 30081860

Group type: EXPERIMENTAL
Intervention: Mobility during learning (experimental block of trials in different postures: seated, standing, or free)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 48
Study: 27222511

Group type: EXPERIMENTAL
Intervention: HDL cholesterol levels
Number of subjects: 1829

Group type: COMPARATOR
Intervention: LDL cholesterol levels between 2.0 and 2.5 mmol/L
Number of subjects: 1829

Group type: COMPARATOR
Intervention: LDL cholesterol levels >2.5 mmol/L
Number of subjects: 1829
Study: 24083887

Group type: EXPERIMENTAL
Intervention: Psychoeducation group intervention combined with routine care
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 60
Study: 22431901

Group type: EXPERIMENTAL
Intervention: rosuvastatin
Number of subjects: 17802

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17802
Study: 20530644

Group type: EXPERIMENTAL
Intervention: Modelling instructional technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Moulding instructional technique
Number of subjects: 16
Study: 18672983

Group type: EXPERIMENTAL
Intervention: Exposed connective tissue group (E group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Fully covered connective tissue group (FC group)
Number of subjects: 20
Study: 15982991

Group type: EXPERIMENTAL
Intervention: 1.5mg/kg p.o. MDMA
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 14632771

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cytosine arabinoside (1 g/m2/2 h) b.i.d. for 4 days with idarubicin (CCI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Two-drug therapy (not specified in detail)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 63
Study: 10562581

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening examination
Number of subjects: 241
Study: 8912148

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.3 U/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 1679065

Group type: EXPERIMENTAL
Intervention: Oxatomide 1 mg/kg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxatomide 2 mg/kg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7101824

Group type: EXPERIMENTAL
Intervention: cytoxan chemotherapy plus surgery plus polychemotherapy (25 patients)
Number of subjects: 75

Group type: COMPARATOR
Intervention: surgery plus polychemotherapy (29 patients)
Number of subjects: 75

Group type: COMPARATOR
Intervention: surgery plus polychemotherapy (21 patients with non-ascitic carcinoma)
Number of subjects: 75
Study: 31995682

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic-valve replacement (TAVR)
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical aortic-valve replacement
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Transfemoral access TAVR
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical replacement (transfemoral access)
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: Transthoracic access TAVR
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgical replacement (transthoracic access)
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 2032

Group type: EXPERIMENTAL
Intervention: TAVR and Surgery
Number of subjects: 2032
Study: 31320747

Group type: COMPARATOR
Intervention: singleton exome sequencing (sES)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: trio exome sequencing (tES)
Number of subjects: 30

Group type: COMPARATOR
Intervention: reflexing to tES after sES
Number of subjects: 30
Study: 29894978

Group type: EXPERIMENTAL
Intervention: Elbow flexed (EF) crutch setup
Number of subjects: 30

Group type: COMPARATOR
Intervention: Elbow extended (EE) crutch setup
Number of subjects: 30
Study: 27502807

Group type: EXPERIMENTAL
Intervention: Hand and foot massage
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 156
Study: 24831445

Group type: EXPERIMENTAL
Intervention: VAS203 (20 mg/kg for 48 hours)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VAS203 (30 mg/kg for 72 hours)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VAS203
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 22371549

Group type: EXPERIMENTAL
Intervention: Targon PF intramedullary nail
Number of subjects: 598

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 598
Study: 19718561

Group type: EXPERIMENTAL
Intervention: rLH 75 IU with rFSH 225 IU
Number of subjects: 80

Group type: COMPARATOR
Intervention: rFSH 225 IU only
Number of subjects: 80
Study: 18299927

Group type: EXPERIMENTAL
Intervention: Pacemaker continuously 'on' for three weeks followed by three weeks with the pacemaker 'off' during the night (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pacemaker 'off' during the night for three weeks followed by pacemaker continuously 'on' for three weeks (Group B)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pacemaker 'off' during the night
Number of subjects: 20
Study: 15994627

Group type: EXPERIMENTAL
Intervention: 20% benzocaine spray
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 12910531

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI) - 4 sessions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (CBI)
Number of subjects: 48
Study: 10996354

Group type: EXPERIMENTAL
Intervention: Patients with primary hypertriglyceridemia and low HDL-C levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normotriglyceridemic subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertriglyceridemic patients
Number of subjects: 0
Study: 9380807

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg once daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nifedipine (20 or 40 mg twice daily)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 21
Study: 8151105

Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) 15 million units, 3 times a week for 4 months plus 150 mg of levamisole for the first 6 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Recombinant alpha interferon 2b (rIFN‐alpha 2b) plus levamisole
Number of subjects: 39
Study: 3731535

Group type: EXPERIMENTAL
Intervention: Low alcohol content beer (64 ml/week)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal drinking habits (452 ml ethanol/week)
Number of subjects: 44
Study: 30307993

Group type: EXPERIMENTAL
Intervention: Well-Child Care (WCC)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Longer duration of visit
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Informal conversations with parents
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Lack of systematic use of developmental screening measures
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Funding and practice nurse support to GPs
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Structured WCC activities with immunisation visits
Number of subjects: 71
Study: 28811096

Group type: EXPERIMENTAL
Intervention: Topical anaesthetic (0.5% proxymetacaine)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 47
Study: 26307558

Group type: EXPERIMENTAL
Intervention: Intermittent boluses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continuous infusion
Number of subjects: 40
Study: 23164997

Group type: EXPERIMENTAL
Intervention: PGA sheet and fibrin glue spray
Number of subjects: 44

Group type: COMPARATOR
Intervention: Primary closure
Number of subjects: 44
Study: 21252701

Group type: COMPARATOR
Intervention: Telmisartan 80 mg
Number of subjects: 405

Group type: COMPARATOR
Intervention: Nifedipine GITS 20 mg
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Combination of Telmisartan 80 mg and Nifedipine GITS 20 mg
Number of subjects: 405
Study: 18719680

Group type: EXPERIMENTAL
Intervention: Very Low-Calorie Diet (VLCD)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Commercial Program
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Self-Guided Approach
Number of subjects: 186

Group type: COMPARATOR
Intervention: Newsletter Control
Number of subjects: 186
Study: 17315536

Group type: EXPERIMENTAL
Intervention: 150 mg irbesartan
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg irbesartan
Number of subjects: 36
Study: 12955680

Group type: EXPERIMENTAL
Intervention: On-line hemodiafiltration (HDF)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional hemodialysis (HD)
Number of subjects: 81

Group type: COMPARATOR
Intervention: High-flux hemodialysis (HD)
Number of subjects: 81
Study: 10877006

Group type: EXPERIMENTAL
Intervention: Nateglinide 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nateglinide 60 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nateglinide 120 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 9174309

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.8 microg/kg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Fentanyl (4.5 microg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (standardized anesthetic regimen)
Number of subjects: 22
Study: 7515730

Group type: EXPERIMENTAL
Intervention: CEMB regimen (cisplatin 50 mg/m2 day 1, vindesin 3 mg/m2 day 1, mitomycin 6 mg/m2 day 2, bleomycin 15 mg/day, day 1 + 2 by continuous infusion)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: CEMB regimen
Number of subjects: 35
Study: 31923551

Group type: EXPERIMENTAL
Intervention: ESC + CBX (200 mg twice daily)
Number of subjects: 47

Group type: COMPARATOR
Intervention: ESC + PBO
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Baseline IL-1β
Number of subjects: 47
Study: 31082494

Group type: EXPERIMENTAL
Intervention: Afatinib in combination with postoperative radiation therapy (PORT)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Afatinib in combination with PORT and weekly docetaxel
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Afatinib in combination with PORT
Number of subjects: 27
Study: 30650497

Group type: EXPERIMENTAL
Intervention: Modified Dachengqi Decoction (500 mL) once a day for 2 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (ileostomy alone)
Number of subjects: 70
Study: 26434024

Group type: EXPERIMENTAL
Intervention: NMES (N = 7)
Number of subjects: 15

Group type: COMPARATOR
Intervention: RT (N = 8)
Number of subjects: 15